In SOD1 amyotrophic lateral sclerosis (SOD1, OMIM 105400), the master switch sits on the ↓ DOWN branch ([F] forced below); the healthy state is the OFF well. The forced corrective direction is to lower s toward OFF branch (polarity: clear). Classification: ✓ Recovers an existing standard. Direction only — no dose, no efficacy magnitude.
The disease maps to an R19 double-well whose corrective lever is read straight off the cusp (barrier 0.5215, γ 1.4443, spinodal 0.6681). The corrective direction is forced [F]; the agent names below are direction-concordant labels at grade [O] (no dose, no efficacy or safety magnitude). This is a research hypothesis offered to experts, not medical advice.
The emergence switch
The switch for SOD1 amyotrophic lateral sclerosis is an R19 double-well emerged from the real proximal-promoter DNA of SOD1. Its geometry is fixed by measured stiffness γ (never fitted); the numbers below are read directly off that cusp.
emergent axis
↓ DOWN [F]
healthy branch
OFF
lesion
GOF
γ (stiffness)
1.4443
barrier
0.5215
spinodal
0.6681
s_on / s_off
1.2018 / -1.2018
fragility
0.35
corrective polarity
clear
forced direction
lower s toward OFF branch
Chemistry feasibility (DIRECTION only [O]). small-molecule recrossing of the fold is geometrically harder (barrier 0.5215 at neutral drive; lower barrier = smaller drive to supply). [O] -- no affinity/potency/dose/efficacy asserted.
The derived corrective lever
The cusp forces a corrective direction: lower s toward OFF branch. This is the load-bearing output of the framework — it is [F] forced, and it is falsifiable. 2 lever families are derived; the lead is h-restore (drive modulator).
Mechanism. remove / oppose the drive (clear the accumulating load that pins the disease branch)
Applies to. allele-agnostic (downstream/environmental tilt)
favoured when the switch is fragile -- a small drive shift recrosses the fold
Falsifier. If clearing/opposing the accumulating SOD1 does NOT relieve the disease branch in a SOD1 model, the h-restore(clear) lever is refuted for this axis.
EXCLUDED: gain-of-function -- the lesion is not a destabilised healthy product to stiffen; the corrective move is to clear/oppose the toxic drive (h-restore)
Falsifier. If a folding-stabiliser/chaperone does NOT re-deepen the healthy well for a residual SOD1 allele (no rescue that a null allele lacks), the gamma-restore lever is refuted; null alleles are excluded by construction.
Agents mapped onto the lever
✓ Agreement with established practice. The corrective direction derived here (lower s toward OFF branch) independently matches an agent already in clinical use for this disease: SOD1-lowering antisense oligonucleotide (tofersen). The geometry recovered known medicine — this is a validation signal for the logic, not a new treatment claim by this kit.
Existing agents whose known action is direction-concordant with the derived lever (status as pinned in the corpus; no dose, no efficacy magnitude).
⚠ Mechanism-direction only — do not self-administer; no dose (unvalidated; set by a physician / national authority); not an approved use.
Direction-only candidate leads (corpus join)
Each lead is surfaced only because its known mechanism points the same way as the derived lever, and each comes with a source and a falsifier. None is a treatment.
Mechanism. Reduces presynaptic glutamate release and modulates voltage-gated sodium channels and glutamatergic neurotransmission, lowering the excitotoxic drive that contributes to motor-neuron loss in ALS, including the SOD1 gain-of-function form. Direction: decrease / oppose the excitotoxic drive. Allele scope: agnostic -- acts on glutamatergic excitotoxicity downstream of the SOD1 lesion (approved across ALS, not SOD1-specific). Pathway-specific to glutamatergic neuroprotection (mapped to SOD1-ALS). A low-cost generic, in contrast to the SOD1-lowering antisense oligonucleotide and IV antioxidant instances of the disease.
✓ This is a rediscovery. Riluzole is approved for amyotrophic lateral sclerosis (all forms, including SOD1); recovered by the direction logic. Low-cost generic, in a disease that is otherwise largely palliative.
Safety (qualitative; no magnitude). post-marketing safety profile on record (approved for amyotrophic lateral sclerosis; low-cost generic; aminotransferase monitoring on label; qualitative; no magnitude)
Falsifier. If riluzole (a pathway decrease agent) clearing/opposing the accumulating load does NOT relieve the DOWN [F] disease branch in a SOD1 model, the h-restore(clear) direction is refuted for riluzole here.
⚠ Mechanism-direction only — do not self-administer; no dose (unvalidated; set by a physician / national authority); not an approved use.
Evidence & provenance
What is reproduced vs. cited for this page.
element
grade
basis
R19 switch & cusp geometry (this page)
[V] verified
emerged from measured promoter γ of SOD1; deterministic, 2×sha256 identical
corrective direction
[F] forced
forced by the cusp sign; falsifiable (see lever falsifiers)
mapped agents / leads
[O] open
direction-concordance only; corpus-pinned (2026-06-21); no dose, no efficacy/safety magnitude
Reading the agent column. VALIDATION SIGNAL -- the agent is already approved / established standard for this disease, so the direction logic recovered known clinical practice. Not a new claim by this kit. GENUINE HYPOTHESIS -- no approved indication for this disease; the direction match is a direction-only, untested [O] lead. Basis field grades the evidence (investigational here / in a related condition / off-label / speculative).